Search results for "clicial trial optimization"

showing 1 items of 1 documents

Fluorouracil and bevacizumab plus anakinra for patients with metastatic colorectal cancer refractory to standard therapies (IRAFU): a single-arm phas…

2018

IF 5.503 (2017); International audience; In preclinical models, IL-1β inhibition could enhance the efficacy of fluorouracil (5-FU). In this phase 2 study, we assessed the activity and safety of 5-FU plus bevacizumab and anakinra (an IL-1β and α inhibitor) in patients with metastatic colorectal (mCRC) refractory to chemotherapy and anti-angiogenic therapy. Eligible patients had unresectable mCRC; were refractory or intolerant to fluoropyrimidine, irinotecan, oxaliplatin, anti-VEGF therapy, and anti-EGFR therapy (for tumors with wild-type KRAS). Patients were treated with a simplified acid folinic plus 5-FU regimen and bevacizumab (5 mg/kg) both administered by intravenous infusion for 30 min…

0301 basic medicinelcsh:Immunologic diseases. Allergymedicine.medical_specialtyBevacizumabImmunologyPhases of clinical research[SDV.CAN]Life Sciences [q-bio]/CancerNeutropeniaGastroenterologyclicial trial optimizationlcsh:RC254-28203 medical and health sciences0302 clinical medicineInternal medicinemedicinetherapeutic trialsImmunology and Allergyil1colorectalnew targetsAnakinrabusiness.industryclinical trialmedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens3. Good healthOxaliplatinIrinotecanRegimen030104 developmental biologyOncologyFluorouracil030220 oncology & carcinogenesischemoimmunotherapymdscbusinesslcsh:RC581-607medicine.drugOncoimmunology
researchProduct